RTRX
Retrophin Inc
Halal Rating :
Last Price
$18.37
Last updated:
Market Cap
-
7D Change
-1.18%
1 Year Change
107.57%
Company Overview
Exchange
Next Earnings Date
Note: Retrophin Inc (RTRX) changed its name to Travere Therapeutics (TVTX) in November 2020.
Travere Therapeutics is a biopharmaceutical company focused on identifying, developing, and commercializing therapies for rare diseases. The company's primary focus is on developing treatments for rare kidney, liver, and metabolic disorders. Their main products include Thiola® and Thiola EC® for the treatment of cystinuria.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $62.9m | $121.82m | - | $2.78m | 0.00% | 2.28% |
| June 30, 2024 | $54.12m | $124.61m | - | $2.79m | 0.00% | 2.24% |
| March 31, 2024 | $41.37m | $180.61m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Retrophin Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.